Treatment Options for ROS1+ Advanced NSCLC

Panelists describe how targeted therapy has become the standard of care for patients with ROS1-positive disease. They discuss the evolution of selective inhibitors, which have demonstrated improvements in systemic and intracranial efficacy compared with earlier therapies. Treatment choice now requires balancing efficacy, safety, and central nervous system activity.

The conversation emphasizes how durability of response and tolerability are crucial in determining therapy selection. Long-term disease control often hinges on maintaining continuous exposure to therapy, requiring careful management of adverse events. Panelists also highlight the value of assessing patient-specific factors such as comorbidities and access to ongoing monitoring.

They conclude by noting that the field continues to advance rapidly, with new generations of inhibitors showing promise for overcoming resistance and improving intracranial outcomes. The integration of molecular retesting at disease progression will further refine individualized treatment strategies.